Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Neurocrine Biosciences Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 37.9× JPMorgan Diversified Return International Eqty ETF's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and Neurocrine Biosciences Inc for 23 Days on average.
| JPIN | NBIX | |
|---|---|---|
Market Cap | $378.77M | $14.36B |
Volume | 13,861 | 1,237,180 |
52-Week High | $77.80 | $185.50 |
52-Week Low | $64.96 | $123.10 |
Typical Hold Time | 120 Days | 23 Days |
Sector | — | Health |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.03 with minimal daily movement (+0.12%). Technical indicators signal strong bearish momentum across moving averages and oscillators, though RSI levels suggest potential oversold conditions. The ETF maintains a strategic focus on international value stocks but lacks current fundamental ratio data. Recent dividend activity shows a $0.51 distribution scheduled for September 2026.
The bearish technical setup dominates the near-term outlook, with resistance clustered at $74. Investment appeal hinges on international equity market recovery and the ETF's value strategy execution. Key risks include global market volatility and currency fluctuations affecting international holdings.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
